Skip to main content
. 2014 Jun 21;7(4):472–478. doi: 10.1016/j.tranon.2014.05.006

Figure 1.

Figure 1

Effects of dose and schedule of systemic therapy on LDR radiosensitization. HepG2 cells were treated with gemcitabine (A), 5-FU (B), or sorafenib (C) at the indicated doses and schedules in combination with LDR (0.26 Gy/h to 4.2 Gy). Cells were assayed for clonogenic survival 24 hours after LDR. Shown are the mean enhancement ratios with standard error (n ≥ 3 for each condition).